Stockreport

Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

Brickell Biotech, Inc.  (BBI) 
PDF BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing inno [Read more]